Read twice and referred to the Committee on Finance.
This bill repeals two specific provisions of Public Law 119–21 (the reconciliation law cited): section 71120, which amended Medicaid cost sharing requirements, and section 71203, which amended the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program. The repeal directs that title XIX (Medicaid) and title XI (the Drug Price Negotiation Program) of the Social Security Act be applied as if those sections and their amendments had never been enacted.
Impact on Medicaid cost sharing: liberals see repeal as protecting beneficiary access, conservatives fear it could reverse cost-control measures.
Relative to its intended legislative type, this bill is a concise statutory repeal that clearly identifies the provisions to be removed and rescinds a named appropriation.
This bill repeals two specific provisions of Public Law 119–21 (the reconciliation law cited): section 71120, which amended Medicaid cost sharing requirements, and section 71203, which amended the exclusion for orphan drugs under the Medicare Drug Price Negotiation Program.
The repeal directs that title XIX (Medicaid) and title XI (the Drug Price Negotiation Program) of the Social Security Act be applied as if those sections and their amendments had never been enacted.
The bill also rescinds amounts appropriated under section 71120(c) of Public Law 119–21.
On content alone the bill is narrowly focused and legally straightforward, which helps its prospects; however, it targets politically charged health-policy items (Medicaid cost-sharing and drug-pricing treatment of orphan drugs), rescinds appropriations, and offers no compromise mechanisms. Those features typically attract concentrated opposition and make enactment of standalone repeal measures difficult, particularly in the Senate.
Relative to its intended legislative type, this bill is a concise statutory repeal that clearly identifies the provisions to be removed and rescinds a named appropriation. It achieves clarity of purpose and directly integrates with the cited statutory titles by instructing that the underlying Social Security Act provisions be applied as if the repealed sections had not existed.
Impact on Medicaid cost sharing: liberals see repeal as protecting beneficiary access, conservatives fear it could reverse cost-control measures.
These are examples from the analysis, not a ranked list of the most-affected groups.
Impact on Medicaid cost sharing: liberals see repeal as protecting beneficiary access, conservatives fear it could reverse cost-control measures.
A mainstream liberal/left-leaning observer would likely view this bill favorably if they interpret the repealed provisions as having increased Medicaid cost sharing or limited the ability to negotiate drug prices for orphan drugs.
They would emphasize restoring access protections for low-income Medicaid enrollees and preserving the government's ability to negotiate or otherwise address high orphan drug prices.
They would also welcome the rescission of any appropriations tied to increased cost sharing.
A centrist/moderate would approach the bill pragmatically: they would recognize the goal of restoring the prior legal baseline but want more information on fiscal, access, and market impacts.
They would neither reflexively support nor oppose repeal without CBO estimates and input from CMS and HHS on effects for states, beneficiaries, and drug markets.
They would focus on tradeoffs between beneficiary protections, taxpayer costs, and incentives for pharmaceutical innovation.
A mainstream conservative would likely be skeptical of this repeal.
They would view overturning recent statutory changes as potentially restoring regulatory or fiscal burdens the prior reforms were intended to address.
On orphan drugs, conservatives may worry that restoring the prior baseline could increase federal interference in drug pricing or alternatively remove protections for innovation—views will vary depending on how they interpret the original amendments.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone the bill is narrowly focused and legally straightforward, which helps its prospects; however, it targets politically charged health-policy items (Medicaid cost-sharing and drug-pricing treatment of orphan drugs), rescinds appropriations, and offers no compromise mechanisms. Those features typically attract concentrated opposition and make enactment of standalone repeal measures difficult, particularly in the Senate.
The bill has not accumulated any surfaced votes yet.
Impact on Medicaid cost sharing: liberals see repeal as protecting beneficiary access, conservatives fear it could reverse cost-control mea…
On content alone the bill is narrowly focused and legally straightforward, which helps its prospects; however, it targets politically charg…
Relative to its intended legislative type, this bill is a concise statutory repeal that clearly identifies the provisions to be removed and rescinds a named appropriation. It achieves clarity of purpose and directly int…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.